Department of Psychology and Neuroscience Center, University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, USA.
Address correspondence to: Kathryn J. Reissner, University of North Carolina, Chapel Hill, CB 3270, 235 E. Cameron Ave., Chapel Hill, North Carolina 27599, USA. Phone: 919.843.9112; E-mail: email@example.com.
First published July 18, 2014 - More info
See the related article beginning on page 3645.
Glutamate excitotoxicity represents a major cellular component of ischemic brain injury. In this issue of the JCI, Soria and colleagues reveal that the cystine/glutamate exchanger is an important source of excitotoxic glutamate in response to ischemia induced by oxygen and glucose deprivation. As the exchanger is a primary determinant of both extracellular glutamate and intracellular glutathione, the findings from this study not only provide important insight into the mechanisms of brain ischemia but also demonstrate the complexity of the yin and yang of glutamate homeostasis and cellular redox balance.
Ischemia is defined as an insufficient blood supply and consequently results in oxygen deprivation and energy depletion in vascularized tissues. Ischemic brain injury most commonly occurs as the result of thrombolytic or embolic stroke but can occur in any condition in which blood or oxygen to the brain is restricted. Ischemic hypoxia in the brain rapidly leads to a series of deleterious cellular events, which culminate in injury and death to neurons, glia, and endothelial cells. The consequences of ischemic damage to neurons, in particular the resulting glutamatergic excitotoxicity, have been well described (for review, see refs. 1, 2). To date, very few effective interventions exist to mitigate brain ischemia–induced damage, which can be associated with a continuum of physiological consequences ranging from disability to death.
Conditions of oxygen deprivation in neural tissue lead to anoxic depolarization (AD, also referred to as peri-infarct depolarization) of membrane potentials, which results from overstimulation of glutamate receptors and a large glutamate-mediated inward current, referred to as either the AD current or ischemia-induced anoxic current (3, 4). However, the source and mechanism of production of excitotoxic glutamate, which mediates oxygen and glucose deprivation–induced (OGD-induced) neuronal damage, are not well defined.
In the current study, Soria et al. (5) used AD depolarization and the anoxic current in pyramidal neurons in acute cortical slices to investigate excitotoxic glutamate release in rodent models of ischemia. One very logical candidate for excitotoxic glutamate release is the induction of reverse transport by glutamate transporters. For example, high-affinity glutamate transporters typically function to move glutamate from the extracellular space into the cell; however, in the presence of decreased extracellular Na+ (such as depolarization), these transporters can function in reverse, thereby releasing glutamate from the cell (6, 7). Interestingly, pharmacological inhibition of glutamate transporters had no effect on the OGD-induced anoxic current, indicating that reverse transport is an unlikely source of excess glutamate (Figure 1). In fact, transporter blockade magnified ischemia-induced damage, indicating that transporters were likely still working in the forward direction. Similarly, blockade of vesicular glutamate release with bafilomycin A1 had no effect on the anoxic current, although miniature excitatory postsynaptic currents (mEPSCs) were effectively blocked (Figure 1). Neither bafilomycin A1 nor tetanus toxin, which also blocks neurotransmitter exocytosis, affected OGD-induced neuronal damage. In contrast, inhibition of the cystine/glutamate exchanger (system xc–) with either S-4-carboxyphenylglycine (CPG) or sulfasalazine (SAS) dramatically reduced the amplitude of the anoxic current as well as OGD-associated neuronal damage (Figure 1). Soria and colleagues (5) went on to measure OGD-induced effects in mice lacking functional cystine/glutamate exchange (Slc7a11sut mice) and found that these mice exhibited a reduction in anoxic currents and neuronal damage following ischemia, further supporting glutamate exchange as a source of excitotoxic glutamate.
Systematic analysis of the source of excitotoxic glutamate during ischemic brain injury. Excitotoxic glutamate (brown circles) released during oxygen and glucose deprivation in culture could potentially derive from reverse transport from high-affinity glutamate transporters (i, yellow), vesicular glutamate release (ii), or the cystine/glutamate exchanger (iii, green). Exchange of glutamate release for cystine uptake by the exchanger is indicated with bidirectional arrows. Soria and colleagues have demonstrated that glutamate released from the cystine/glutamate exchanger activates extrasynaptic NR2B–containing receptors (iii, purple), as opposed to synaptic NR2A–containing receptors (blue).
These results from Soria and coworkers (5) intriguingly suggest that extracellular glutamate derived from the cystine/glutamate exchanger mediates neuronal damage induced by ischemia. Indeed, system xc– has been well described as a major source of extrasynaptic glutamate (8). Release of glutamate by the exchanger is coupled with uptake of cystine at a 1:1 ratio. Cystine then serves as an intracellular precursor for the generation of the antioxidant glutathione. In this way, the exchanger also serves an important role in antioxidant-mediated cellular protection (9–11).
While release of glutamate from the exchanger has been linked with stimulation of presynaptic inhibitory metabotropic glutamate receptors in the ventral striatum (12), evidence coupling this source of glutamate with stimulation of extrasynaptic excitatory receptors is lacking. Because it is known that NMDA currents mediate excitotoxic damage (13), Soria et al. tested the hypothesis that exchanger-derived glutamate stimulates NMDA receptor–mediated (NMDAR-mediated) glutamate currents (5). Soria and colleagues applied cystine to acute slices and observed an inward current, which was blocked by administration of the NMDAR antagonist D-AP5. Moreover, this current was blocked by treatment with the system xc– antagonist CPG. Nonetheless, while the results of Soria and colleagues (5) indicate that NMDARs are stimulated by xc–-derived glutamate, they do not differentiate between synaptic and extrasynaptic NMDARs, which contribute differentially to postsynaptic signaling as well as to the adaptive and pathological consequences of NMDAR activation (14). To this point, pharmacological inhibition of extrasynaptic NR2B subunit–containing NMDARs impaired the anoxic current, whereas blockade of the synaptic NR2A subunit–containing receptors did not affect current amplitude, thus implicating extrasynaptic NR2B–containing receptors as the likely mediators of glutamate excitotoxicity. NR2B antagonists ifenprodil and RO-256981 reduced the anoxic current, while NR2A antagonists did not alter the current without effect. Moreover, NR2A antagonists had no effect on OGD-mediated neuronal death, while inhibitors of the extrasynaptic NR2B–containing receptors were protective against cell death subsequent to OGD (5).
Collectively, the results from Soria and colleagues indicate that anoxic currents and neuronal damage induced by OGD are mediated by glutamate derived from system xc– via activation of NR2B-containing extrasynaptic NMDARs (5). But, is the exchanger stimulated by ischemia? Real-time quantitative PCR and Western blot analysis of the catalytic subunit of the exchanger (xCT) indicated that mRNA and protein were markedly upregulated 1 hour and 4 hours, respectively, following chemical ischemia in culture. Ischemia also induced enhanced functional transport of [14C] L-cystine. Additionally, Soria and colleagues induced transient focal ischemia in a rat model of middle cerebral artery occlusion (MCAO) and measured xCT function by radioligand imaging via PET (5). Acute ipsilateral MCAO resulted in tracer accumulation, supporting ischemia-induced upregulation of the exchanger in vivo.
In sum, the study by Soria et al. (5) identifies the cystine/glutamate exchanger as a major source of excitotoxic glutamate during ischemia in culture. In response to oxidative stress, both expression and activity of the cysteine/glutamate exchanger is upregulated (15); hence, this process may represent an adaptive attempt to compensate for ischemia-induced oxidative stress. Ironically, this potentially protective mechanism leads to damaging consequences. For example, the cystine pro-drug N-acetylcysteine (NAC) activates system xc– and has previously been reported to have protective effects against brain ischemia (16, 17); therefore, NAC has been proposed as a possible target for the treatment of ischemic brain injury (18). However, the study by Soria and colleagues (5) clearly indicates that caution must be taken when considering the use of an activator of system xc– to reduce ischemia-associated damage.
Finally, it is important to note that pharmacological inhibition or genetic deletion of system xc– reduced, but did not completely block, the anoxic current and ischemia-induced cell death promoted by OGD, raising the possibility that glutamate from additional sources also contributes. Indeed, there are a number of additional nonvesicular sources of glutamate (for review see ref. 10); therefore, continued study into the mechanisms of glutamate release in response to ischemia is warranted for the development of more effective treatment strategies.
This study, together with other recent reports, challenges the simple view that in cases of pathophysiology, system xc– predominantly functions in an antioxidative, protective role. Quite the opposite: this complex system provides an intriguing example of how, despite the critical benefits of glutamate release in exchange for uptake of cystine, too much of a good thing really is a bad thing.
This work was supported by NIH grant DA031790 (to K.J. Reissner).
Conflict of interest: The author has declared that no conflict of interest exists.
Reference information:J Clin Invest. 2014;124(8):3279–3281. doi:10.1172/JCI76627.
See the related article beginning on page 3645.
Copyright © 2015 American Society for Clinical Investigation